Probiodrug sponsors 5th Biannual NUBIN Symposium on Biomarkers in Neurodegenerative Diseases
Posted: 29 October 2014 | Probiodrug AG
Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, has announced it is the Silver sponsor of the 5th Biannual NUBIN Symposium on Biomarkers in Neurodegenerative Disease taking place on October 29th and 30th in Amsterdam.
Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, has announced it is the Silver sponsor of the 5th Biannual NUBIN Symposium on Biomarkers in Neurodegenerative Disease taking place on October 29th and 30th in Amsterdam.
The Neuro Unit Biomarkers for Inflammation and Neurodegeneration (NUBIN) symposium, organized by the VU University Medical Center (VUmc) and NeuroCampus Amsterdam (NCA), a world leading neuroscience center in Amsterdam, brings together leading clinicians specializing in neuroinflammatory and neurodegenerative diseases such as Alzheimer’s Disease and Multiple Sclerosis, who will highlight important topics on biomarker research today. This year, the following three topics have been selected: ‘New technologies & new biomarkers’, ‘Blood based biomarkers’ and ‘Biomarkers as surrogate outcome measures’.
Dr Inge Lues, Chief Development Officer of Probiodrug said; “The Alzheimer’s Center at the VUmc is among the world leaders in Alzheimer’s research. As Silver Sponsors of the event, Probiodrug is proud to be part of this renowned Symposium that brings together experts from around the globe with a common goal to identify new diagnostic and therapeutic biomarkers for Alzheimer’s Disease.”
Reduce preclinical failures with smarter off-target profiling
24 September 2025 | 15:00PM BST | FREE Webinar
Join this webinar to hear from Dr Emilie Desfosses as she shares insights into how in vitro and in silico methods can support more informed, human-relevant safety decisions -especially as ethical and regulatory changes continue to reshape preclinical research.
What you’ll learn:
- Approaches for prioritizing follow-up studies and refining risk mitigation strategies
- How to interpret hit profiles from binding and functional assays
- Strategies for identifying organ systems at risk based on target activity modulation
- How to use visualization tools to assess safety margins and compare compound profiles
Register Now – It’s Free!
The agenda for the 5th Biannual Symposium can be found here.
In January 2014, Probiodrug and the VUmc Alzheimer Center started a collaboration to assess newly developed molecular biomarker assays for their diagnostic, pharmacodynamic, and therapeutic potential. The assays are designed to detect the presence and concentration of pyroglutamated amyloid beta (pGlu-Abeta), a highly toxic peptide produced by the enzyme glutaminyl cyclase (QC). PGlu-Abeta has been correlated with cognitive decline in individuals with Alzheimer’s Disease and this collaboration seeks to correlate pGlu Abeta concentrations in cerebrospinal fluid (CSF) with disease stage.
Related topics
Biomarkers
Related conditions
Alzheimer’s disease, Multiple Sclerosis
Related organisations
Probiodrug
